clement, Author at BaseLaunch

Features

NousCom wins over investors

NousCom, a Basel-based oncology company, raised 42 million euros in a Series B financing round. It will use the new funds to drive development of…

clement07.11.2017

Features

Novartis, Amgen and Banner aim for Alzheimer’s prevention with new BACE trials

clement03.11.2017

Features

Novartis to strengthen oncology portfolio with new acquisition

The Basel-based pharmaceutical company Novartis has entered into a memorandum of understanding to acquire Advanced Accelerator Applications, a French radiopharmaceutical company that specializes in nuclear…

clement30.10.2017

Features

Roivant enters into partnership with AstraZeneca

Basel – The pharmaceutical company Roivant Sciences will develop a drug for AstraZeneca, marking the first time the two companies will work together.

clement23.10.2017

Features

Roche invests in novel antibiotics

The Basel-based pharmaceutical company Roche is collaborating with the U.S. biotechnology firm Warp Drive Bio, which developed a proprietary technology platform to discover and develop…

clement17.10.2017

Features

“You should always have something crazy cooking on the back burner”

When Jennifer Doudna gave her keynote at Basel Life in September, the auditorium in the Congress Center was packed. Susan Gasser, Professor of Molecular Biology at…

clement17.10.2017

Features

Myovant therapy effective against uterine fibroids

The Basel-based pharmaceutical company Myovant Sciences has published positive study results for its therapy relugolix, which has now been shown to be effective and safe…

clement03.10.2017

Interviews

clement

NousCom wins over investors

Novartis, Amgen and Banner aim for Alzheimer’s prevention with new BACE trials

Novartis to strengthen oncology portfolio with new acquisition

Roivant enters into partnership with AstraZeneca

Roche invests in novel antibiotics

“You should always have something crazy cooking on the back burner”

Myovant therapy effective against uterine fibroids

Interview with Markus Hosang from Biomed Partners about companies the VC is keeping an eye on

Pfizer spends billions to develop new drugs. It’s not satisfied. So it’s launching a startup

After 20 years, a drug that silences genes succeeds

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us